Skip to the guide
EXACT 41

Hormone and gut signalling / EDUCATIONAL GUIDE

Ipamorelin

Ipamorelin 10 mg box packaging mockup
Packaging mockup
10 mg€29.90

Research aims, observed effects
and the limits of the evidence.

Limited clinical evidenceSources checked 6 September 2026

THE IDEA IN EVERYDAY TERMS

Growth-hormone release and gut movement

Ipamorelin acts at the ghrelin receptor and has been studied as a growth-hormone secretagogue—a substance that prompts hormone release. That explains interest in its endocrine effects. Researchers have also investigated whether its effects on gut movement could help the bowel start working again after abdominal surgery.

Read the background ↗

Early pharmacology + randomized surgical trial

What has actually been shown?

The postoperative trial measured how quickly patients could tolerate a solid meal. The ipamorelin group had a shorter median time, but the difference was not statistically significant, so the main result did not establish a benefit. Triggering hormone release also does not, by itself, demonstrate more muscle, faster recovery, better sleep or an anti-aging effect.

Read the evidence ↗

01 / OVERVIEW

What is Ipamorelin?

Ipamorelin is a ghrelin-receptor agonist investigated for growth-hormone release and gastrointestinal motility. [1]

02 / RESEARCH AIMS

Why it is studied.

A randomized phase 2 study examined recovery of bowel function after abdominal surgery, a specific clinical question distinct from fitness or anti-aging claims. [1]

03 / RESEARCH MAP

Following the research question.

Ghrelin-receptor activity can influence endocrine and gastrointestinal responses. Early pharmacology described ipamorelin as a growth-hormone secretagogue. [3]

Ipamorelin research map: Ghrelin receptor; Physiological response; Postoperative studyRESEARCH MAP / IPAMORELIN01Ghrelin receptor02Physiological response03Postoperative study
Conceptual research map, not a molecular structure or a proven chain of clinical effects. [3]

04 / OBSERVED EFFECTS

What the evidence shows.

In the postoperative study, the difference in time to a tolerated meal was not statistically significant. A numerical difference alone does not demonstrate efficacy. [1]

Study context

Randomized human study

Key distinction

Primary result not significant

Uncertainty

Other uses unestablished

A selected-source overview, not a systematic review. Research findings are not verified effects of an independently supplied sample.

05 / SAFETY AND LIMITATIONS

Risks belong beside the findings.

FDA flags immunogenicity concerns and serious events reported during intravenous clinical research. [2]

Results in surgical patients do not establish safety or benefit for other populations or routes.

06 / REFERENCES

Go to the source.

  1. Ipamorelin for postoperative ileus ↗

    2014. Randomized, placebo-controlled phase 2 study.

  2. FDA — Safety concerns for certain compounded substances ↗

    Regulatory safety assessment; route and formulation matter.

  3. Ipamorelin pharmacology ↗

    European Journal of Endocrinology, 1998. Primary pharmacology study.